Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KBA-1704 is an investigational anti-desmoglein 2 (DSG2) monoclonal antibody therapy developed by Kling Biotherapeutics. It is being studied as an antineoplastic immunotherapy, with its primary mechanism of action involving the inhibition or modulation of desmoglein 2, a cell adhesion molecule implicated in cancer progression. The drug is currently in preclinical development for cancer indications, including colonic cancer and Lynch syndrome II. As a new molecular entity, it represents a novel approach to targeting DSG2 in oncology[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KBA-1704.